Perigon Wealth Management LLC Makes New $13.38 Million Investment in Thermo Fisher Scientific Inc. $TMO

Perigon Wealth Management LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 26,698 shares of the medical research company’s stock, valued at approximately $13,385,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Commerzbank Aktiengesellschaft FI purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $32,967,000. Trust Co. of Vermont purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $25,326,000. Principle Wealth Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth about $1,677,000. UP Strategic Wealth Investment Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth approximately $361,000. Finally, Focused Wealth Management Inc acquired a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $215,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on TMO shares. Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Jefferies Financial Group reaffirmed a “buy” rating and set a $630.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Barclays increased their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 price target for the company. Finally, Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 5,850 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the transaction, the vice president directly owned 14,784 shares in the company, valued at approximately $8,574,720. This trade represents a 28.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the transaction, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 52,053 shares of company stock valued at $30,643,589. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $590.00 on Wednesday. The firm has a fifty day moving average price of $533.64 and a 200 day moving average price of $508.36. The stock has a market cap of $218.15 billion, a PE ratio of 31.74, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.